Study Evaluating Treatment of Melanoma After Surgery

What we are studying

The purpose of this study is to test the two drugs dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) together to see how well they work compared to two placebos. We want to find out what effects, good or bad, these two drugs have on people who have a type of skin cancer called melanoma. The study drugs dabrafenib and trametinib together are not yet approved for doctors to prescribe to patients.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Must have recently or will have surgery for melanoma
  • The melanoma must have started on the skin. Per Staging Guidelines you must be recently considered a Stage III before your last surgery but now have no evidence of disease
  • Must be BRAF positive which the study will verify if you do not know

What is involved

  • Patients will be evaluated by a surgeon and/or medical oncologist from this hospital before being registered to this study.
  • The goal is to begin a 12 month treatment with the study pills around 3 months after surgery. During this time you will need to get tests; visit the clinic/office/hospital on schedule; and tell the study staff about any changes to your health.

Compensation

Set amount for travel reimbursement on treatment days.

Contact Information

Study Coordinator
Joyce Fenstermaker
Email
jfenster@wakehealth.edu
Phone
336-713-3155

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.